US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SITE Centers Corp.

5.42

-0.0700-1.28%

Post-market: 5.470.0500+0.92%18:05 EDT

Volume:1.72M

Turnover:9.34M

Market Cap:284.35M

PE:1.61

High:5.52

Open:5.51

Low:5.38

Close:5.49

52wk High:13.27

52wk Low:5.35

Shares:52.46M

Float Shares:52.25M

Volume Ratio:1.27

T/O Rate:3.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):3.36

EPS(LYR):3.36

ROE:41.78%

ROA:-0.21%

PB:0.85

PE(LYR):1.61

Loading ...

Overview Company News Filings

Site Centers price target lowered to $8 from $8.82 at Citi

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Site Centers price target lowered to $10 from $12 at Piper Sandler

Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Research Update

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

SITE Centers Reports Q3 Net Loss of $6.2 Million and $380.9 Million in Property Sales

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SITC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SITC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SITC\",,,,,undefined,":{"symbol":"SITC","market":"US","secType":"STK","nameCN":"SITE Centers Corp.","latestPrice":5.42,"timestamp":1774036800000,"preClose":5.49,"halted":0,"volume":1718315,"hourTrading":{"tag":"盘后","latestPrice":5.47,"preClose":5.42,"latestTime":"18:05 EDT","volume":332303,"amount":1801128.3665,"timestamp":1774044327268,"change":0.05,"changeRate":0.009225,"amplitude":0.009225},"delay":0,"changeRate":-0.012750455373406244,"floatShares":52248129,"shares":52462340,"eps":3.36,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"03-20 16:00:00 EDT","open":5.51,"high":5.515,"low":5.38,"amount":9335322.904013999,"amplitude":0.02459,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.36,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":5.49,"aum":0,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":5.47,"preClose":5.42,"latestTime":"18:05 EDT","volume":332303,"amount":1801128.3665,"timestamp":1774044327268,"change":0.05,"changeRate":0.009225,"amplitude":0.009225},"volumeRatio":1.267029036537547,"impliedVol":0.4268,"impliedVolPercentile":0.5783},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SITC\",,,,,undefined,":{"symbol":"SITC","floatShares":52248129,"roa":"-0.21%","roe":"41.78%","lyrEps":3.36,"volumeRatio":1.267029036537547,"shares":52462340,"dividePrice":0,"high":5.515,"amplitude":0.02459,"preClose":5.49,"low":5.38,"week52Low":5.345,"pbRate":"0.85","psRate":"2.31","week52High":13.27,"institutionHeld":0.9407,"latestPrice":5.42,"eps":3.36,"divideRate":0,"volume":1718315,"delay":0,"ttmEps":3.36,"open":5.51,"prevYearClose":6.42,"prevWeekClose":5.67,"prevMonthClose":6.16,"prevQuarterClose":6.42,"fiveDayClose":5.67,"twentyDayClose":6.65,"sixtyDayClose":6.34,"dividendPayoutRate":2.0096080103273013,"dividendFrequency":"Q","dividendGrowthYears":1,"dividendGrowthRate":5.490384615384615,"fiveYearAvgDividendRate":0.24738110475797534},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SITC\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"SITC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1772139600000,"name":null,"time":"Post Market","dateTimestamp":1772082000000,"actualEps":null},{"date":"2025-12-15","symbol":"SITC","amount":1,"announcedDate":"2025-12-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-15","defaultRemindTime":1765809000000,"name":"SITE Centers Corp.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-30","payableDate":"2025-12-15","currency":"USD","dateTimestamp":1765774800000,"payDate":"2025-12-30"},{"market":"US","date":"2025-11-05","symbol":"SITC","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":0},{"date":"2025-10-31","symbol":"SITC","amount":1,"announcedDate":"2025-10-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-31","defaultRemindTime":1761917400000,"name":"SITE Centers Corp.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-10-31","currency":"USD","dateTimestamp":1761883200000,"payDate":"2025-11-14"},{"date":"2025-09-02","symbol":"SITC","amount":3.25,"announcedDate":"2025-08-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-15","defaultRemindTime":1756819800000,"name":"SITE Centers Corp.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-15","currency":"USD","dateTimestamp":1756785600000,"payDate":"2025-08-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SITC\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-07","recordDate":"2016-06-09","paymentDate":"2016-07-06","value":0.19,"currency":"USD"},{"executeDate":"2016-09-21","recordDate":"2016-09-23","paymentDate":"2016-10-11","value":0.19,"currency":"USD"},{"executeDate":"2016-12-09","recordDate":"2016-12-13","paymentDate":"2017-01-05","value":0.19,"currency":"USD"},{"executeDate":"2018-12-13","recordDate":"2018-12-14","paymentDate":"2019-01-04","value":0.2,"currency":"USD"},{"executeDate":"2019-03-14","recordDate":"2019-03-15","paymentDate":"2019-04-02","value":0.2,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SITC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1772251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SITC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SITC","date":"2026-03-20","current":1.613095,"percent":0.201359,"low":0.676862,"twenty":1.609306,"median":14.579393,"eighty":29.741148,"high":191.31255,"avg":29.390935,"sd":42.715301,"marketCap":288018246},"quantilePoints":[{"date":"2021-03-26","current":72.948075,"twenty":-21.330192,"median":10.413749,"eighty":20.72975,"marketCap":2605778201},{"date":"2021-04-01","current":81.578891,"twenty":-21.330192,"median":10.413749,"eighty":20.72975,"marketCap":2914079580},{"date":"2021-04-09","current":81.815352,"twenty":-21.346772,"median":10.405985,"eighty":20.72975,"marketCap":2922526188},{"date":"2021-04-16","current":83.175,"twenty":-21.346772,"median":10.405985,"eighty":20.72975,"marketCap":2971094181},{"date":"2021-04-23","current":181.722513,"twenty":-21.346772,"median":10.405985,"eighty":20.72975,"marketCap":3161244840},{"date":"2021-04-30","current":179.052037,"twenty":-21.330192,"median":10.413749,"eighty":20.72975,"marketCap":3114789242},{"date":"2021-05-07","current":179.416211,"twenty":-21.031751,"median":10.45851,"eighty":20.808051,"marketCap":3121124406},{"date":"2021-05-14","current":179.29482,"twenty":-20.26078,"median":10.628891,"eighty":20.953183,"marketCap":3119012685},{"date":"2021-05-21","current":174.439171,"twenty":-19.86286,"median":10.760125,"eighty":21.17332,"marketCap":3034543824},{"date":"2021-05-28","current":181.722644,"twenty":-19.59758,"median":10.843553,"eighty":21.350211,"marketCap":3161247115},{"date":"2021-06-04","current":182.936556,"twenty":-19.353025,"median":10.873231,"eighty":21.458393,"marketCap":3182364330},{"date":"2021-06-11","current":190.584202,"twenty":-19.149919,"median":10.903393,"eighty":21.641205,"marketCap":3315402786},{"date":"2021-06-18","current":176.409606,"twenty":-18.959249,"median":10.936392,"eighty":21.742594,"marketCap":3068821509},{"date":"2021-06-25","current":181.236134,"twenty":-18.814174,"median":10.978796,"eighty":21.900316,"marketCap":3152783794},{"date":"2021-07-02","current":180.029502,"twenty":-18.727129,"median":11.057988,"eighty":22.173572,"marketCap":3131793223},{"date":"2021-07-09","current":182.684093,"twenty":-18.586199,"median":11.106983,"eighty":22.491948,"marketCap":3177972479},{"date":"2021-07-16","current":180.874145,"twenty":-18.233873,"median":11.137144,"eighty":22.927256,"marketCap":3146486622},{"date":"2021-07-23","current":182.925419,"twenty":-17.939578,"median":11.182387,"eighty":23.358886,"marketCap":3182170593},{"date":"2021-07-30","current":76.747214,"twenty":-16.640313,"median":11.272517,"eighty":23.834401,"marketCap":3367514261},{"date":"2021-08-06","current":77.618242,"twenty":-13.565429,"median":11.299781,"eighty":24.16559,"marketCap":3405733212},{"date":"2021-08-13","current":75.972967,"twenty":-13.112133,"median":11.361721,"eighty":24.324535,"marketCap":3333541859},{"date":"2021-08-20","current":75.15033,"twenty":-12.911344,"median":11.454504,"eighty":24.606186,"marketCap":3297446183},{"date":"2021-08-27","current":78.392489,"twenty":-12.075456,"median":11.512149,"eighty":24.862689,"marketCap":3439705613},{"date":"2021-09-03","current":78.198927,"twenty":-11.874284,"median":11.597108,"eighty":25.159211,"marketCap":3431212513},{"date":"2021-09-10","current":73.940569,"twenty":-11.75983,"median":11.640455,"eighty":25.890766,"marketCap":3244364306},{"date":"2021-09-17","current":76.166529,"twenty":-11.543848,"median":11.70682,"eighty":26.965347,"marketCap":3342034960},{"date":"2021-09-24","current":75.440673,"twenty":-11.486784,"median":11.716711,"eighty":27.504909,"marketCap":3310185834},{"date":"2021-10-01","current":78.102146,"twenty":-11.402384,"median":11.75737,"eighty":30.033057,"marketCap":3426965962},{"date":"2021-10-08","current":79.74742,"twenty":-11.350665,"median":11.786459,"eighty":31.459278,"marketCap":3499157315},{"date":"2021-10-15","current":80.957181,"twenty":-11.268524,"median":11.806148,"eighty":32.112171,"marketCap":3552239192},{"date":"2021-10-22","current":79.457078,"twenty":-11.223146,"median":11.817362,"eighty":32.264301,"marketCap":3486417664},{"date":"2021-10-29","current":52.174647,"twenty":-11.138413,"median":11.840788,"eighty":32.536868,"marketCap":3373351803},{"date":"2021-11-05","current":56.705862,"twenty":-11.085883,"median":11.869677,"eighty":32.866484,"marketCap":3666317535},{"date":"2021-11-12","current":54.735769,"twenty":-11.037694,"median":11.879948,"eighty":33.08834,"marketCap":3538941130},{"date":"2021-11-19","current":54.47309,"twenty":-10.975399,"median":11.890583,"eighty":33.690522,"marketCap":3521957609},{"date":"2021-11-26","current":51.911968,"twenty":-10.953528,"median":11.911488,"eighty":34.888549,"marketCap":3356368282},{"date":"2021-12-03","current":50.532902,"twenty":-10.89362,"median":11.945735,"eighty":35.560457,"marketCap":3267204798},{"date":"2021-12-10","current":50.138884,"twenty":-10.817339,"median":11.974047,"eighty":36.333787,"marketCap":3241729517},{"date":"2021-12-17","current":49.219507,"twenty":-10.600022,"median":12.007676,"eighty":37.012034,"marketCap":3182287194},{"date":"2021-12-23","current":50.007544,"twenty":-10.56133,"median":12.028522,"eighty":38.153012,"marketCap":3233237757},{"date":"2021-12-31","current":51.977638,"twenty":-10.39631,"median":12.06347,"eighty":44.31339,"marketCap":3360614162},{"date":"2022-01-07","current":52.634336,"twenty":-9.93569,"median":12.078465,"eighty":48.589077,"marketCap":3403072964},{"date":"2022-01-14","current":52.568666,"twenty":-9.638521,"median":12.105553,"eighty":49.71203,"marketCap":3398827084},{"date":"2022-01-21","current":47.938946,"twenty":-9.582274,"median":12.145744,"eighty":50.033812,"marketCap":3099492531},{"date":"2022-01-28","current":49.121002,"twenty":-9.497901,"median":12.173878,"eighty":50.020678,"marketCap":3175918374},{"date":"2022-02-04","current":48.10312,"twenty":-9.334514,"median":12.273341,"eighty":50.020678,"marketCap":3110107231},{"date":"2022-02-11","current":25.801244,"twenty":-9.280832,"median":12.332854,"eighty":50.020678,"marketCap":3223478403},{"date":"2022-02-18","current":26.190377,"twenty":-9.20764,"median":13.101808,"eighty":50.020678,"marketCap":3272094798},{"date":"2022-02-25","current":27.08718,"twenty":-9.116217,"median":13.301412,"eighty":50.020678,"marketCap":3384136804},{"date":"2022-03-04","current":27.070261,"twenty":-9.081397,"median":13.410358,"eighty":50.020678,"marketCap":3382023040},{"date":"2022-03-11","current":27.188693,"twenty":-8.932741,"median":13.565493,"eighty":50.020678,"marketCap":3396819390},{"date":"2022-03-18","current":27.662423,"twenty":-8.804174,"median":13.68492,"eighty":50.020678,"marketCap":3456004794},{"date":"2022-03-25","current":27.39172,"twenty":-8.566101,"median":13.926879,"eighty":50.020678,"marketCap":3422184563},{"date":"2022-04-01","current":28.491854,"twenty":-8.494418,"median":14.014538,"eighty":50.020678,"marketCap":3559629780},{"date":"2022-04-08","current":27.224423,"twenty":-8.455252,"median":14.140785,"eighty":50.020678,"marketCap":3401283260},{"date":"2022-04-14","current":27.731395,"twenty":-8.413437,"median":14.285152,"eighty":50.020678,"marketCap":3464621868},{"date":"2022-04-22","current":27.900386,"twenty":-8.335201,"median":14.519704,"eighty":50.020678,"marketCap":3485734737},{"date":"2022-04-29","current":27.689747,"twenty":-8.214908,"median":14.675724,"eighty":50.020678,"marketCap":3402073026},{"date":"2022-05-06","current":26.74934,"twenty":-8.105599,"median":14.753735,"eighty":50.020678,"marketCap":3286530923},{"date":"2022-05-13","current":26.226892,"twenty":-8.073018,"median":14.835984,"eighty":50.020678,"marketCap":3222340866},{"date":"2022-05-20","current":24.119685,"twenty":-8.034568,"median":14.935298,"eighty":50.020678,"marketCap":2963440969},{"date":"2022-05-27","current":27.863896,"twenty":-7.999038,"median":15.080449,"eighty":50.020678,"marketCap":3423469712},{"date":"2022-06-03","current":26.74934,"twenty":-7.950425,"median":15.095031,"eighty":50.020678,"marketCap":3286530923},{"date":"2022-06-10","current":23.823631,"twenty":-7.90537,"median":15.234506,"eighty":50.020678,"marketCap":2927066603},{"date":"2022-06-17","current":22.674245,"twenty":-7.776056,"median":15.309635,"eighty":50.020678,"marketCap":2785848478},{"date":"2022-06-24","current":23.858461,"twenty":-7.729466,"median":15.462379,"eighty":50.033812,"marketCap":2931345940},{"date":"2022-07-01","current":23.753971,"twenty":-7.570482,"median":15.660607,"eighty":50.033812,"marketCap":2918507929},{"date":"2022-07-08","current":23.231523,"twenty":-7.513609,"median":15.75812,"eighty":50.033812,"marketCap":2854317872},{"date":"2022-07-15","current":23.318598,"twenty":-7.390816,"median":17.01476,"eighty":50.033812,"marketCap":2865016215},{"date":"2022-07-22","current":24.224175,"twenty":-7.304216,"median":17.915542,"eighty":50.033812,"marketCap":2976278980},{"date":"2022-07-29","current":19.389716,"twenty":-7.195641,"median":18.065672,"eighty":50.033812,"marketCap":3129209334},{"date":"2022-08-05","current":18.580152,"twenty":-7.014684,"median":18.26585,"eighty":50.033812,"marketCap":2998557884},{"date":"2022-08-12","current":19.933849,"twenty":-7.014684,"median":18.491041,"eighty":50.033812,"marketCap":3217024244},{"date":"2022-08-19","current":19.190643,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":3097081928},{"date":"2022-08-26","current":17.903304,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2889324703},{"date":"2022-09-02","current":17.000839,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2743680463},{"date":"2022-09-09","current":17.823675,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2876473741},{"date":"2022-09-16","current":17.027382,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2747964117},{"date":"2022-09-23","current":14.996837,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2420264577},{"date":"2022-09-30","current":14.213817,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2293896781},{"date":"2022-10-07","current":14.187273,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2289613127},{"date":"2022-10-14","current":14.492519,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2338875149},{"date":"2022-10-21","current":15.341897,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2475952081},{"date":"2022-10-28","current":13.19515,"twenty":-7.014684,"median":18.641171,"eighty":50.033812,"marketCap":2632643607},{"date":"2022-11-04","current":13.216467,"twenty":-7.014684,"median":18.61615,"eighty":50.033812,"marketCap":2636896666},{"date":"2022-11-11","current":13.983875,"twenty":-7.014684,"median":18.491041,"eighty":50.033812,"marketCap":2790006795},{"date":"2022-11-18","current":14.090459,"twenty":-7.014684,"median":18.354536,"eighty":50.033812,"marketCap":2811272091},{"date":"2022-11-25","current":14.229019,"twenty":-7.014684,"median":18.265846,"eighty":50.033812,"marketCap":2838916975},{"date":"2022-12-02","current":14.420871,"twenty":-7.014684,"median":18.022748,"eighty":50.033812,"marketCap":2877194508},{"date":"2022-12-09","current":14.143752,"twenty":-7.014684,"median":17.915542,"eighty":50.033812,"marketCap":2821904739},{"date":"2022-12-16","current":13.962558,"twenty":-7.014684,"median":17.61133,"eighty":50.033812,"marketCap":2785753736},{"date":"2022-12-23","current":14.516797,"twenty":-7.014684,"median":17.199912,"eighty":50.033812,"marketCap":2896333274},{"date":"2022-12-30","current":14.559431,"twenty":-7.014684,"median":17.053926,"eighty":50.033812,"marketCap":2904839392},{"date":"2023-01-06","current":13.930583,"twenty":-7.014684,"median":16.934482,"eighty":49.311445,"marketCap":2779374147},{"date":"2023-01-13","current":14.090459,"twenty":-7.014684,"median":16.483249,"eighty":48.726983,"marketCap":2811272091},{"date":"2023-01-20","current":13.728072,"twenty":-7.014684,"median":15.75812,"eighty":48.536541,"marketCap":2738970086},{"date":"2023-01-27","current":14.314287,"twenty":-7.014684,"median":15.639909,"eighty":48.346098,"marketCap":2855929212},{"date":"2023-02-03","current":14.697991,"twenty":-7.014684,"median":15.341897,"eighty":47.722236,"marketCap":2932484277},{"date":"2023-02-10","current":17.431293,"twenty":-7.014684,"median":15.251052,"eighty":38.894647,"marketCap":2940990395},{"date":"2023-02-17","current":17.343066,"twenty":8.24554,"median":15.341897,"eighty":38.102301,"marketCap":2926104688},{"date":"2023-02-24","current":16.869169,"twenty":9.088908,"median":15.504586,"eighty":38.102301,"marketCap":2846149307},{"date":"2023-03-03","current":16.582193,"twenty":9.410881,"median":15.699613,"eighty":38.102301,"marketCap":2797731086},{"date":"2023-03-10","current":15.184747,"twenty":9.562713,"median":15.855634,"eighty":38.102301,"marketCap":2561955404},{"date":"2023-03-17","current":14.585842,"twenty":9.657722,"median":15.855634,"eighty":38.102301,"marketCap":2460908683},{"date":"2023-03-24","current":14.336298,"twenty":9.754238,"median":15.855634,"eighty":38.102301,"marketCap":2418805882},{"date":"2023-03-31","current":15.321997,"twenty":9.852263,"median":15.82638,"eighty":38.051591,"marketCap":2585111944},{"date":"2023-04-06","current":14.872818,"twenty":9.90203,"median":15.82638,"eighty":38.051591,"marketCap":2509326903},{"date":"2023-04-14","current":14.735568,"twenty":10.022676,"median":15.855634,"eighty":38.102301,"marketCap":2486170363},{"date":"2023-04-21","current":14.880945,"twenty":10.100022,"median":15.855634,"eighty":38.102301,"marketCap":2510698158},{"date":"2023-04-28","current":14.923106,"twenty":10.170468,"median":15.855634,"eighty":38.102301,"marketCap":2537912886},{"date":"2023-05-05","current":14.67685,"twenty":10.236823,"median":15.855634,"eighty":38.102301,"marketCap":2496033135},{"date":"2023-05-12","current":14.332092,"twenty":10.260952,"median":16.032017,"eighty":38.343175,"marketCap":2437401484},{"date":"2023-05-22","current":14.492158,"twenty":10.41424,"median":16.464097,"eighty":38.717161,"marketCap":2464623322},{"date":"2023-06-16","current":16.252887,"twenty":10.785762,"median":16.750679,"eighty":44.31339,"marketCap":2764063539},{"date":"2023-07-28","current":25.197394,"twenty":11.00463,"median":17.27564,"eighty":48.162223,"marketCap":2898431050},{"date":"2023-08-04","current":25.397618,"twenty":11.073225,"median":17.435046,"eighty":48.162223,"marketCap":2921462610},{"date":"2023-08-11","current":25.361232,"twenty":11.128106,"median":17.546519,"eighty":48.162223,"marketCap":2917277134},{"date":"2023-08-18","current":23.614691,"twenty":11.160198,"median":17.909423,"eighty":48.162223,"marketCap":2716374261},{"date":"2023-08-25","current":23.396373,"twenty":11.239305,"median":18.019188,"eighty":48.162223,"marketCap":2691261402},{"date":"2023-09-01","current":24.287837,"twenty":11.28108,"median":18.215803,"eighty":48.162223,"marketCap":2793805577},{"date":"2023-09-08","current":24.688086,"twenty":11.315392,"median":18.347724,"eighty":48.162223,"marketCap":2839845818},{"date":"2023-09-15","current":25.070142,"twenty":11.396477,"median":18.491041,"eighty":48.162223,"marketCap":2883793322},{"date":"2023-09-22","current":23.269021,"twenty":11.501531,"median":18.611422,"eighty":48.162223,"marketCap":2676612234},{"date":"2023-09-29","current":22.632261,"twenty":11.565241,"median":18.741258,"eighty":48.162223,"marketCap":2603366395},{"date":"2023-10-06","current":21.431514,"twenty":11.628551,"median":18.862611,"eighty":48.162223,"marketCap":2465245670},{"date":"2023-10-13","current":22.068274,"twenty":11.70682,"median":18.941436,"eighty":48.181924,"marketCap":2538491509},{"date":"2023-10-20","current":21.249583,"twenty":11.715669,"median":19.06654,"eighty":48.181924,"marketCap":2444318287},{"date":"2023-10-27","current":20.721982,"twenty":11.751549,"median":19.203657,"eighty":48.201625,"marketCap":2383628878},{"date":"2023-11-03","current":26.691875,"twenty":11.782919,"median":19.301672,"eighty":48.201625,"marketCap":2601817183},{"date":"2023-11-10","current":27.379035,"twenty":11.804156,"median":19.390769,"eighty":48.201625,"marketCap":2668798800},{"date":"2023-11-17","current":28.15209,"twenty":11.816178,"median":19.513046,"eighty":48.201625,"marketCap":2744153119},{"date":"2023-11-24","current":28.173564,"twenty":11.823271,"median":19.79217,"eighty":48.201625,"marketCap":2746246295},{"date":"2023-12-01","current":28.32388,"twenty":11.861543,"median":19.975607,"eighty":48.201625,"marketCap":2760898524},{"date":"2023-12-08","current":28.903671,"twenty":11.874946,"median":20.117452,"eighty":48.201625,"marketCap":2817414263},{"date":"2023-12-15","current":31.029573,"twenty":11.888522,"median":20.221885,"eighty":48.201625,"marketCap":3024638640},{"date":"2023-12-22","current":29.590831,"twenty":11.91034,"median":20.427474,"eighty":48.201625,"marketCap":2884395880},{"date":"2023-12-29","current":29.891464,"twenty":11.93663,"median":20.530884,"eighty":48.227893,"marketCap":2913700337},{"date":"2024-01-05","current":28.753355,"twenty":11.951044,"median":20.666113,"eighty":48.254161,"marketCap":2802762034},{"date":"2024-01-12","current":29.633779,"twenty":11.976942,"median":20.72975,"eighty":48.254161,"marketCap":2888582231},{"date":"2024-01-19","current":29.053988,"twenty":12.012067,"median":20.854609,"eighty":48.280428,"marketCap":2832066492},{"date":"2024-01-26","current":29.741148,"twenty":12.050866,"median":20.968389,"eighty":48.254161,"marketCap":2899048109},{"date":"2024-02-02","current":28.968093,"twenty":12.078465,"median":21.176825,"eighty":48.254161,"marketCap":2823693789},{"date":"2024-02-09","current":29.590831,"twenty":12.105337,"median":21.286574,"eighty":48.254161,"marketCap":2884395880},{"date":"2024-02-16","current":11.273805,"twenty":12.121334,"median":21.376935,"eighty":48.254161,"marketCap":2995483680},{"date":"2024-02-23","current":11.068969,"twenty":12.102013,"median":21.36612,"eighty":48.254161,"marketCap":2941058400},{"date":"2024-03-01","current":10.700192,"twenty":12.076695,"median":21.244812,"eighty":48.227893,"marketCap":2843073179},{"date":"2024-03-08","current":11.117799,"twenty":12.048043,"median":21.244812,"eighty":48.227893,"marketCap":2954032589},{"date":"2024-03-15","current":11.039005,"twenty":12.007676,"median":21.208433,"eighty":48.227893,"marketCap":2933096851},{"date":"2024-03-22","current":11.401457,"twenty":11.975106,"median":21.131335,"eighty":48.227893,"marketCap":3029401245},{"date":"2024-03-28","current":11.409336,"twenty":11.945735,"median":20.971378,"eighty":48.227893,"marketCap":3031494818},{"date":"2024-04-05","current":11.033059,"twenty":11.914716,"median":20.721982,"eighty":48.254161,"marketCap":2931516936},{"date":"2024-04-12","current":10.946309,"twenty":11.890995,"median":20.267582,"eighty":48.254161,"marketCap":2908467125},{"date":"2024-04-19","current":10.686058,"twenty":11.87564,"median":20.117452,"eighty":48.254161,"marketCap":2839317690},{"date":"2024-04-26","current":10.741263,"twenty":11.874946,"median":20.042474,"eighty":48.227893,"marketCap":2853985752},{"date":"2024-05-03","current":12.801669,"twenty":11.874946,"median":20.042474,"eighty":48.227893,"marketCap":2904276250},{"date":"2024-05-10","current":12.912467,"twenty":11.874946,"median":20.042474,"eighty":48.227893,"marketCap":2929412621},{"date":"2024-05-17","current":13.180322,"twenty":11.874946,"median":20.042474,"eighty":48.227893,"marketCap":2990180122},{"date":"2024-05-24","current":13.097195,"twenty":11.886038,"median":20.042474,"eighty":48.227893,"marketCap":2971321243},{"date":"2024-05-31","current":13.115667,"twenty":11.888522,"median":20.042474,"eighty":48.227893,"marketCap":2975512105},{"date":"2024-06-07","current":13.549777,"twenty":11.91541,"median":20.042474,"eighty":48.227893,"marketCap":3073997365},{"date":"2024-06-14","current":13.577487,"twenty":11.9744,"median":20.067408,"eighty":48.254161,"marketCap":3080283658},{"date":"2024-06-21","current":13.355813,"twenty":11.976264,"median":20.09243,"eighty":48.280428,"marketCap":3029993312},{"date":"2024-06-28","current":13.217268,"twenty":12.015039,"median":20.119651,"eighty":48.339531,"marketCap":2998561846},{"date":"2024-07-05","current":13.383523,"twenty":12.067158,"median":20.119651,"eighty":48.339531,"marketCap":3036279605},{"date":"2024-07-12","current":13.90076,"twenty":12.108178,"median":20.119651,"eighty":48.339531,"marketCap":3153623745},{"date":"2024-07-15","current":14.067015,"twenty":12.125501,"median":20.119651,"eighty":48.339531,"marketCap":3191341504},{"date":"2024-08-02","current":7.046799,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3239829432},{"date":"2024-08-09","current":6.955638,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3197917020},{"date":"2024-08-16","current":7.028567,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3231446949},{"date":"2024-08-23","current":6.900941,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3172769527},{"date":"2024-08-30","current":6.862197,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3154956753},{"date":"2024-09-06","current":6.584154,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3027123898},{"date":"2024-09-13","current":6.750524,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3103614049},{"date":"2024-09-20","current":6.780151,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3117235583},{"date":"2024-09-27","current":6.750524,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":3103614049},{"date":"2024-10-04","current":1.931488,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":888019212},{"date":"2024-10-11","current":1.961116,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":901640745},{"date":"2024-10-18","current":1.916675,"twenty":12.504257,"median":20.573716,"eighty":48.45117,"marketCap":881208445},{"date":"2024-10-25","current":1.956558,"twenty":12.199762,"median":20.573716,"eighty":48.45117,"marketCap":899545125},{"date":"2024-10-31","current":0.676862,"twenty":11.943647,"median":20.573716,"eighty":48.45117,"marketCap":860776145},{"date":"2024-11-08","current":1.136209,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":834056982},{"date":"2024-11-15","current":1.12479,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":825674500},{"date":"2024-11-22","current":1.154211,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":847271401},{"date":"2024-11-29","current":1.108499,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":813716098},{"date":"2024-12-06","current":1.0985,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":806375876},{"date":"2024-12-13","current":1.112785,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":816861908},{"date":"2024-12-20","current":1.072073,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":786976716},{"date":"2024-12-27","current":1.0935,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":802705764},{"date":"2025-01-03","current":1.071359,"twenty":11.975812,"median":20.642908,"eighty":48.464304,"marketCap":786452415},{"date":"2025-01-10","current":1.067788,"twenty":12.08223,"median":20.682445,"eighty":48.464304,"marketCap":783830906},{"date":"2025-01-17","current":1.0935,"twenty":12.08223,"median":20.682445,"eighty":48.464304,"marketCap":802705764},{"date":"2025-01-24","current":1.089215,"twenty":12.08223,"median":20.682445,"eighty":48.464304,"marketCap":799559955},{"date":"2025-01-31","current":1.087786,"twenty":12.08223,"median":20.682445,"eighty":48.464304,"marketCap":798511352},{"date":"2025-02-07","current":1.082072,"twenty":12.08223,"median":20.682445,"eighty":48.464304,"marketCap":794316939},{"date":"2025-02-14","current":1.078501,"twenty":11.967771,"median":20.573716,"eighty":48.464304,"marketCap":791695431},{"date":"2025-02-21","current":1.05136,"twenty":11.815098,"median":20.171841,"eighty":48.464304,"marketCap":771771969},{"date":"2025-02-28","current":1.360481,"twenty":11.549812,"median":20.042474,"eighty":48.464304,"marketCap":723536221},{"date":"2025-03-07","current":1.287534,"twenty":11.27329,"median":19.867491,"eighty":48.464304,"marketCap":684741350},{"date":"2025-03-14","current":1.248099,"twenty":11.172328,"median":19.867235,"eighty":48.464304,"marketCap":663769180},{"date":"2025-03-21","current":1.261901,"twenty":11.161297,"median":19.867235,"eighty":48.464304,"marketCap":671109440},{"date":"2025-03-28","current":1.258944,"twenty":11.155562,"median":19.867235,"eighty":48.464304,"marketCap":669536527},{"date":"2025-04-04","current":1.190919,"twenty":11.155562,"median":19.867235,"eighty":48.464304,"marketCap":633359534},{"date":"2025-04-11","current":1.122895,"twenty":11.140266,"median":19.79217,"eighty":48.464304,"marketCap":597182540},{"date":"2025-04-17","current":1.148527,"twenty":11.117799,"median":19.79217,"eighty":48.464304,"marketCap":610814451},{"date":"2025-04-25","current":1.17547,"twenty":11.123737,"median":19.867235,"eighty":48.464304,"marketCap":625143243},{"date":"2025-05-02","current":1.17547,"twenty":11.111923,"median":19.867235,"eighty":48.464304,"marketCap":625143243},{"date":"2025-05-09","current":1.131612,"twenty":11.111923,"median":19.867235,"eighty":48.464304,"marketCap":631961020},{"date":"2025-05-16","current":1.159785,"twenty":11.111923,"median":19.867235,"eighty":48.464304,"marketCap":647694490},{"date":"2025-05-23","current":1.103439,"twenty":11.111122,"median":19.867235,"eighty":48.464304,"marketCap":616227551},{"date":"2025-05-30","current":1.125977,"twenty":11.105833,"median":19.867235,"eighty":48.464304,"marketCap":628814327},{"date":"2025-06-06","current":1.094987,"twenty":11.039005,"median":19.867235,"eighty":48.464304,"marketCap":611507510},{"date":"2025-06-13","current":1.115647,"twenty":10.945567,"median":19.867235,"eighty":48.464304,"marketCap":623045388},{"date":"2025-06-20","current":1.161663,"twenty":10.857981,"median":19.867363,"eighty":48.464304,"marketCap":648743388},{"date":"2025-06-27","current":1.218009,"twenty":10.802082,"median":19.867363,"eighty":48.464304,"marketCap":680210327},{"date":"2025-07-03","current":1.1025,"twenty":10.753772,"median":19.867363,"eighty":48.464304,"marketCap":615703102},{"date":"2025-07-11","current":1.089352,"twenty":10.637162,"median":19.867363,"eighty":48.464304,"marketCap":608360816},{"date":"2025-07-18","current":1.056484,"twenty":7.018084,"median":19.867363,"eighty":48.464304,"marketCap":590005102},{"date":"2025-07-25","current":1.033946,"twenty":6.987088,"median":19.867363,"eighty":48.464304,"marketCap":577418326},{"date":"2025-08-01","current":1.011407,"twenty":6.957461,"median":19.867363,"eighty":48.464304,"marketCap":564831551},{"date":"2025-08-08","current":1.626032,"twenty":6.89342,"median":19.867363,"eighty":48.464304,"marketCap":596298490},{"date":"2025-08-15","current":1.641763,"twenty":6.868123,"median":19.500535,"eighty":48.464304,"marketCap":602067429},{"date":"2025-08-22","current":1.693247,"twenty":6.770579,"median":19.466887,"eighty":48.464304,"marketCap":620947592},{"date":"2025-08-29","current":1.749021,"twenty":6.709729,"median":19.390769,"eighty":48.464304,"marketCap":641401102},{"date":"2025-09-05","current":1.338581,"twenty":6.554982,"median":19.341779,"eighty":48.464304,"marketCap":490884245},{"date":"2025-09-12","current":1.291387,"twenty":3.785717,"median":19.229181,"eighty":48.464304,"marketCap":473577428},{"date":"2025-09-19","current":1.274226,"twenty":1.967725,"median":19.06654,"eighty":48.464304,"marketCap":467284041},{"date":"2025-09-26","current":1.248484,"twenty":1.945391,"median":19.06654,"eighty":48.464304,"marketCap":457843959},{"date":"2025-10-03","current":1.257064,"twenty":1.924424,"median":19.022419,"eighty":48.464304,"marketCap":460990653},{"date":"2025-10-10","current":1.228462,"twenty":1.886591,"median":18.733698,"eighty":48.464304,"marketCap":450501673},{"date":"2025-10-17","current":1.231322,"twenty":1.731002,"median":18.666417,"eighty":48.464304,"marketCap":451550571},{"date":"2025-10-24","current":1.254204,"twenty":1.68581,"median":18.580152,"eighty":48.464304,"marketCap":459941755},{"date":"2025-10-31","current":1.19843,"twenty":1.637473,"median":17.963026,"eighty":48.464304,"marketCap":439488245},{"date":"2025-11-07","current":9.987778,"twenty":1.612017,"median":17.467224,"eighty":48.464304,"marketCap":375630354},{"date":"2025-11-14","current":9.625094,"twenty":1.612017,"median":17.422109,"eighty":48.464304,"marketCap":361990146},{"date":"2025-11-21","current":9.47165,"twenty":1.612017,"median":17.145116,"eighty":48.464304,"marketCap":356219288},{"date":"2025-11-28","current":10.280716,"twenty":1.612017,"median":17.014111,"eighty":48.464304,"marketCap":386647445},{"date":"2025-12-05","current":10.071475,"twenty":1.612017,"median":16.844214,"eighty":48.464304,"marketCap":378778094},{"date":"2025-12-12","current":10.18307,"twenty":1.612017,"median":16.600909,"eighty":48.464304,"marketCap":382975082},{"date":"2025-12-19","current":8.843927,"twenty":1.612017,"median":16.348916,"eighty":48.464304,"marketCap":332611235},{"date":"2025-12-26","current":9.136864,"twenty":1.612017,"median":15.852277,"eighty":48.464304,"marketCap":343628327},{"date":"2026-01-02","current":8.955522,"twenty":1.612017,"median":15.401366,"eighty":48.464304,"marketCap":336808222},{"date":"2026-01-09","current":8.843927,"twenty":1.612017,"median":15.321997,"eighty":48.464304,"marketCap":332611235},{"date":"2026-01-16","current":8.746281,"twenty":1.612017,"median":15.132592,"eighty":48.464304,"marketCap":328938871},{"date":"2026-01-23","current":8.52309,"twenty":1.612017,"median":15.041943,"eighty":48.464304,"marketCap":320544897},{"date":"2026-01-30","current":8.52309,"twenty":1.612017,"median":14.996909,"eighty":48.464304,"marketCap":320544897},{"date":"2026-02-06","current":8.885775,"twenty":1.612017,"median":14.929155,"eighty":48.464304,"marketCap":334185105},{"date":"2026-02-13","current":8.955522,"twenty":1.612017,"median":14.866579,"eighty":48.464304,"marketCap":336808222},{"date":"2026-02-20","current":9.24846,"twenty":1.612017,"median":14.797147,"eighty":48.3855,"marketCap":347825314},{"date":"2026-02-27","current":1.990997,"twenty":1.612017,"median":14.712222,"eighty":48.03745,"marketCap":354120795},{"date":"2026-03-06","current":1.843516,"twenty":1.612017,"median":14.670949,"eighty":30.746119,"marketCap":327889625},{"date":"2026-03-13","current":1.704884,"twenty":1.612017,"median":14.607869,"eighty":29.882874,"marketCap":303232325},{"date":"2026-03-20","current":1.619345,"twenty":1.609306,"median":14.579393,"eighty":29.741148,"marketCap":288018246}],"updateTime":1774251692544},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SITC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583511671","title":"Site Centers price target lowered to $8 from $8.82 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511671?lang=en_us&edition=fundamental","pubTime":"2025-11-14 04:50","pubTimestamp":1763067025,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Site Centers (SITC) to $8 from $8.82 and keeps a Neutral rating on the shares following Q3 results. The fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-8-from-8-82-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-8-from-8-82-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SITC","BK4231","BK4080"],"gpt_icon":0},{"id":"2583605435","title":"IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583605435","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583605435?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:45","pubTimestamp":1763037900,"startTime":"0","endTime":"0","summary":"R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187221/0/en/IMUNON-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4509","SG9999011746.SGD","BK4080","LU1023057109.AUD","BK4571","BK4526","SITC","IE00BYTNYN87.SGD","BK4552","LU2039709279.SGD","BK4108","TME","LU0456842615.SGD","IE00B12V2V27.USD","IE00BYQNZ168.SGD","01698","BK4531","LU0359201612.USD","BK4565","LU0359202008.SGD","OS","BK4231","BK4563","BK4535","BK4097","BK4548"],"gpt_icon":0},{"id":"2583679215","title":"Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583679215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583679215?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden. Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors. Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index. Anticipate cash runway into the first quarter of 2027. WALTHAM, Mass., Nov. 13, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","L","MSS","XLO","LU0210528500.USD","TMB","LU2487616109.SGD","SITC","ORR","LU0053666078.USD","BK4113","BK4080","LENZ","BK4588","BK4231","BK4022","BK4232","BK4585","BK4139","BK4107","R","BK4007"],"gpt_icon":0},{"id":"2583567674","title":"Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567674","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567674?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing. Conference Call and Webcast today at 8:00 a.m. Eastern Time. PRINCETON, N.J., Nov. 13, 2025  -- PDS Biotechnology Corporation  , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update.\"Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the encouraging data from our now completed VERSATILE-002 trial\", said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. \"We believe the positive PFS data offers an important opportunity to shorten the trial duration and time to regulatory submission while maintaining mOS as the endpoint for full FDA approval. Importantly, we believe this approach may also accelerate the availab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","03160","PDS","PDSB","BK4555","TM","BK4092","BK4604","BK4231","BK4139","BK4022","BK4099","SITC","ADC","BK4080","BK4585","BK4232","R","BK4202","NCI"],"gpt_icon":0},{"id":"2582787286","title":"Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2582787286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582787286?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:30","pubTimestamp":1762781400,"startTime":"0","endTime":"0","summary":"Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting  The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184579/0/en/Akari-Therapeutics-Presents-Promising-Immuno-Oncology-Data-for-its-Novel-Splicing-Targeted-ADC-Payload-Driving-Immune-Activation-Both-as-Single-Agent-and-in-Combination-with-Anti-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4539","BK4231","LENZ","SITC","BK4007","BK4139","BK4080"],"gpt_icon":0},{"id":"2582391872","title":"PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391872","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582391872?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:30","pubTimestamp":1762781400,"startTime":"0","endTime":"0","summary":"Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapyPDS01ADC reprograms natural killer (NK) cells to possess characteristics th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184578/37149/en/PDS-Biotechnology-Announces-Translational-Data-Showing-Strong-Immunological-and-Clinical-Activity-of-PDS0101-and-PDS01ADC-Presented-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","BK4533","BK4550","LU0320765646.SGD","IE00B2B36J28.USD","LU1929549753.HKD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU2361044949.HKD","CCR","SG9999002232.USD","SG9999014567.USD","LU2361044865.SGD","BK4559","LU1934455863.HKD","LU2361045086.USD","IE0003851619.USD","LU1066051811.HKD","LU1974910355.USD","LU2112291526.USD","LU0211331839.USD","LU1430594728.SGD","LU0861579265.USD","PDS","LU0234572021.USD","LU1989771016.USD","BK4588","LU0208291251.USD","LU2023250843.SGD","NCI","SG9999015341.SGD","SG9999015358.SGD","BK4202","LU1699723380.USD","BK4092","MRK","LU0265550946.USD","LU1917777945.USD","IE00BYQNZ168.SGD","LU1069347547.HKD","SG9999002224.SGD","ADC","SITC","SG9999014542.SGD","IE000M9KFDE8.USD","BK4534","LU0070302665.USD","LU1023059063.AUD","01308"],"gpt_icon":0},{"id":"2582872393","title":"Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872393","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872393?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"v=ZGqtE6-kgmM About Calidi Calidi Biotherapeutics  is a clinical-stage company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184495/0/en/Calidi-Biotherapeutics-Presents-New-Data-on-its-Therapeutic-Lead-CLD-401-at-the-2025-SITC-Annual-Meeting-and-Holds-Its-First-Investor-Day-at-SITC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003795394.USD","IE00BYQNZ168.SGD","BK4571","BK4548","IE00B12V2V27.USD","TME","LU0359202008.SGD","LU2039709279.SGD","LU0456842615.SGD","SG9999011746.SGD","BK4080","BK4563","SITC","BK4565","BK4531","LU1023057109.AUD","LU0359201612.USD","BK4108","BK4552","BK4535","BK1103","IE0003851619.USD","01698","BK4509","IE00BYTNYN87.SGD","BK1541","BK4231","BK4526","01308"],"gpt_icon":0},{"id":"2582723698","title":"Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582723698","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582723698?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"– Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184504/0/en/Verrica-Pharmaceuticals-Presents-New-Data-on-VP-315-from-its-Phase-2-Clinical-Trial-in-Basal-Cell-Carcinoma-at-the-40th-Society-for-Immunotherapy-of-Cancer-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456842615.SGD","BK4531","BK4565","BCC","LU1023057109.AUD","BK4104","BK4108","BK4571","BK4567","TME","BK4563","BK4552","BK4548","LU0359202008.SGD","LU2039709279.SGD","SITC","LU0359201612.USD","01698","BK4509","IE00B12V2V27.USD","BK4526","IE00BYTNYN87.SGD","IE00BYQNZ168.SGD","BK4231","BK4535","BK4080","SG9999011746.SGD"],"gpt_icon":0},{"id":"2582209198","title":"Site Centers price target lowered to $10 from $12 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2582209198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582209198?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:16","pubTimestamp":1762773377,"startTime":"0","endTime":"0","summary":"Piper Sandler lowered the firm’s price target on Site Centers (SITC) to $10 from $12 and keeps an Overweight rating on the shares. Third quarter sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-10-from-12-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-10-from-12-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SITC","BK4080","BK4231"],"gpt_icon":0},{"id":"2581628886","title":"Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581628886","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581628886?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":"40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden . Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need. \"These compelling new Phase 2 data for vilastobart in combination with atezolizumab demonstrated a 40% objective response rate in heavily pre-pretreated patients with MSS mCRC without liver metastases and with high plasma TMB, signifying an important advance in our understanding of response to novel immunotherapy in MSS mCRC,\" said Katarina Luptakova, M.D., chief medical officer of Xilio. \"In addition, these data showed a statistically significant correlation between plasma-based TMB and response. We estimate that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could ultimately benefit from combination treatment with vilastobart and a substantially greater prevalence of patients w","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TME","01308","LU2487616109.SGD","SG9999011746.SGD","01698","BK4535","BK4232","BK4552","BK4107","BK4231","BK4509","BK4139","IE00BYTNYN87.SGD","L","LU0359201612.USD","ORR","LU0359202008.SGD","BK4022","IE0003795394.USD","BK4007","R","BK4539","BK4585","MSS","BK4531","XLO","LU2039709279.SGD","BK4548","TMB","BK4571","IE0003851619.USD","IE00B12V2V27.USD","BK1541","BK4526","IE00BYQNZ168.SGD","LENZ","LU1023057109.AUD","LU0456842615.SGD","BK4080","BK4113","BK1103","LU0053666078.USD","LU0210528500.USD","BK4108","SITC","BK4565","BK4563","BK4588"],"gpt_icon":0},{"id":"2581888667","title":"Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888667","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888667?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:01","pubTimestamp":1762524060,"startTime":"0","endTime":"0","summary":"Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183720/0/en/Xilio-Therapeutics-Highlights-Portfolio-of-Differentiated-Masked-Immunotherapies-at-Society-for-Immunotherapy-of-Cancer-SITC-40th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IE00BYTNYN87.SGD","IE0003851619.USD","MSS","IE00B12V2V27.USD","BK4548","BK4565","BK4526","SITC","PD","BK1541","01698","01308","BK4113","LU2039709279.SGD","BK4535","BK4080","IE00BYQNZ168.SGD","LU1169590202.USD","LENZ","BK4571","BK4552","BK4563","BK4231","TME","BK4531","BK4023","LU1169589451.USD","LU0359202008.SGD","BK4509","LU1023057109.AUD","BK4108","IE0003795394.USD","LU0359201612.USD","SG9999011746.SGD","BK4139","BK1103","LU0456842615.SGD","BK4007"],"gpt_icon":0},{"id":"2581886625","title":"BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886625","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886625?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524000,"startTime":"0","endTime":"0","summary":"— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183685/0/en/BioAtla-s-Mecbotamab-Vedotin-Mec-V-an-AXL-targeting-ADC-Demonstrates-a-Median-Overall-Survival-OS-of-21-5-months-in-Subtypes-of-Refractory-Soft-Tissue-Sarcomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4124","BK4231","BK4080","SITC","OS","ADC","AXL","BK4097","BCAB"],"gpt_icon":0},{"id":"2581886688","title":"ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886688","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886688?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:15","pubTimestamp":1762521300,"startTime":"0","endTime":"0","summary":"ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183623/0/en/ALX-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD4GTW91.USD","IE00BMG7P819.SGD","BK4195","BK4080","PFS","BK4566","SITC","IE00BMG7P702.HKD","BK4231","ALX","BK4211","IE00BMG7P926.USD","IE00BD4GTT62.SGD","HR","BK4097","BK4144","ADC","IE00BMG7P587.USD","BK4203","ORR","TRP","OS","IE00BD4GTV84.USD","IE00BMG7P694.USD","BK4225"],"gpt_icon":0},{"id":"2581888267","title":"BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888267","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888267?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183561/0/en/BriaCell-Presents-Robust-Anti-Cancer-Activity-of-Bria-OTS-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK1103","IE00B12V2V27.USD","BCTX","IE0003851619.USD","NCI","SG9999011746.SGD","SITC","IE00BYTNYN87.SGD","IE00BYQNZ168.SGD","IE0003795394.USD","01308","BK4202","BK1541","BK4139","BK4080"],"gpt_icon":0},{"id":"2581888114","title":"Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888114","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888114?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Nov.  07, 2025  (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183563/0/en/Context-Therapeutics-Highlights-CT-95-and-CT-202-Programs-at-2025-SITC-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01308","BK4007","BK4548","LU2413666426.HKD","BK4585","IE00B12V2V27.USD","BK4231","LU1093756325.SGD","IE0003795394.USD","IE00BYQNZ168.SGD","IE00B7SZL793.SGD","IE00BYQQ9H92.USD","BK4006","BK4539","LU2211817866.USD","BK4139","BK1541","BK4588","IE00BYTNYN87.SGD","LU2065731478.USD","SITC","LU1721428933.USD","IE00BFXG0V08.USD","IE0003851619.USD","IE00B19Z4B17.USD","BK4533","SG9999011746.SGD","IE0031619046.USD","LU0963586101.USD","BK4080","MTD","LENZ","BK4567","BK4121","LU2413666699.HKD","IE00B66KJ199.SGD","LU0347712357.USD","CRS","BK1103","BK4187","LU1093756168.USD"],"gpt_icon":0},{"id":"2581307963","title":"Research Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581307963","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581307963?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:12","pubTimestamp":1762499520,"startTime":"0","endTime":"0","summary":"Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody iSCIB1+ in late-stage melanoma at SITC 2025  Data from SCOPE trial show a potential new benchmark in effic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183379/0/en/Research-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4211","BK4231","ORR","PFS","SITC","BK4195"],"gpt_icon":0},{"id":"2581954740","title":"Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2581954740","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581954740?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432200,"startTime":"0","endTime":"0","summary":"Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ and ReSPECT-LM, and future directions and needsHOUSTON, Nov.  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182450/0/en/Plus-Therapeutics-Highlights-ReSPECT-LM-Clinical-Trial-Results-at-40th-SITC-Annual-Meeting-Melanoma-Research-Foundation-Brain-Metastases-Summit-4-0.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","BK4139","BK4135","IE00BYQNZ168.SGD","01308","SG9999011746.SGD","IE00B12V2V27.USD","SITC","BK4539","NCI","BK4231","SMMF","CNS","BK4080","IE0003851619.USD","BK1541","IE00BYTNYN87.SGD","BK4211","IE0003795394.USD","BK1103","LENZ","BK4007"],"gpt_icon":0},{"id":"2581609523","title":"Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581609523","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581609523?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432200,"startTime":"0","endTime":"0","summary":"IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182459/0/en/Crescent-Biopharma-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","SITC"],"gpt_icon":0},{"id":"2581702679","title":"SITE Centers Reports Q3 Net Loss of $6.2 Million and $380.9 Million in Property Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702679","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702679?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:24","pubTimestamp":1762377885,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Site Centers Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL4TSLSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SITC","BK4080","BK4231"],"gpt_icon":0},{"id":"2581580779","title":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2581580779","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581580779?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:07","pubTimestamp":1762351620,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  05, 2025  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181582/0/en/MiNK-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results-and-Highlight-Clinical-and-Corporate-Milestones-Advancing-iNKT-Platform-Toward-Pivotal-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139","BK4080","SITC","BK4231"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":118,"code":"91000000","status":"200"}]}}